Bio: José E. Manautou holds the Boehringer Ingelheim Pharmaceuticals, Inc. Chair in Mechanistic Toxicology and serves as Department Head of Pharmaceutical Sciences and Professor of Toxicology at the University of Connecticut School of Pharmacy. His research examines the biochemical and molecular determinants of xenobiotic-induced liver injury and the compensatory mechanisms that bolster hepatic resilience to repeated toxicant exposure. He has authored over 200 publications and is a Fellow of both the Academy of Toxicological Sciences and the American Society of Pharmacology and Experimental Therapeutics. Dr. Manautou is Co-Editor-in-Chief of Current Opinion in Toxicology and President of the International Union of Toxicology (IUTOX). He has contributed to several National Academy of Sciences, Engineering, and Medicine committees and served on numerous NIH panels. He is a Treasurer and a member of the Board of Trustees of the Health and Environmental Sciences Institute (HESI). His awards include the Society of Toxicology Achievement Award, the Distinguished Toxicology Award from the Hispanic Organization of Toxicologists, and the UConn Provost Outstanding Service Award. He earned a BS in Pharmacy (University of Puerto Rico), a PhD in Pharmacology and Toxicology (Purdue University), completed postdoctoral training at UConn, and undertook sabbatical research at the Academic Medical Center in Amsterdam.

Abstract: Generative AI (GenAI) is revolutionizing scientific publishing and research by enhancing knowledge discovery, efficiency, and interdisciplinary collaboration. Researchers increasingly use GenAI tools to analyze large datasets, summarize findings, and streamline workflows such as reviewer selection, journal matching, and plagiarism detection. This adoption accelerates innovation and improves communication within the scientific community. However, the rapid integration of GenAI raises ethical concerns regarding transparency, accountability, and research integrity. Ensuring responsible use involves promoting awareness of policies and fostering a collaborative effort among researchers, stakeholders, and policymakers. Developing trustworthy AI tools is essential to maintain rigorous and reliable scientific knowledge while mitigating potential risks. Addressing these challenges and opportunities will enable the scientific community to harness GenAI’s full potential, driving progress responsibly and ethically. Overall, while GenAI offers significant benefits for accelerating discovery and collaboration, careful oversight is vital to ensure its role remains beneficial and trustworthy in advancing science.